Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 1/2022

01-01-2022 | COVID-19 | Original Article

Association of blood glucose level and prognosis of inpatients with coexistent diabetes and COVID-19

Authors: Weiwei Duan, Liangyu Li, Xuesong Li, Mengyan Zhu, Lingxiang Wu, Wei Wu, Kening Li, Yuan Liang, Rong Ding, Wenhua You, Ziyu Wang, Bin Huang, Min Wu, Tingting Zhang, Jie Li, Yan Li, Jiaofang Shao, Changsong Lin, Pengping Li, Qianghu Wang, Shukui Wang, Xinyi Xia, Yu Liu, Sali Lyu

Published in: Endocrine | Issue 1/2022

Login to get access

Abstract

Type 2 diabetes (T2D) increases the risk of coronavirus disease (COVID-19). This study investigates the association between glucose control of COVID-19 patients with T2D in first 7 days after hospital admission and prognosis. A total of 252 infected inpatients with T2D in China were included. Well-controlled blood glucose was defined as stable fasting blood glucose (FBG) levels in the range of 3.9–7.8 mmol/L during first 7 days using indicators of average (FBGA), maximum (FBGM) or first-time (FBG1) FBG levels. The primary endpoint was admission to intensive care unit or death. Hazard ratio (HR) of poorly controlled glucose level group compared with well-controlled group were 4.96 (P = 0.021) for FBGM and 5.55 (P = 0.014) for FBGA. Well-controlled blood glucose levels in first 7 days could improve the prognosis of COVID-19 inpatients with diabetes.
Appendix
Available only for authorised users
Literature
1.
Z. Wu, J.M. McGoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 323(13), 1239–1242 (2019).CrossRef
2.
X. Yang, Y. Yu, J. Xu, H. Shu, J. Xia, H. Liu, Y. Wu, L. Zhang, Z. Yu, M. Fang, T. Yu, Y. Wang, S. Pan, X. Zou, S. Yuan, Y. Shang, Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respiratory Med. 8, 475–481 (2020)CrossRef
3.
J.J. Zhang, X. Dong, Y.Y. Cao, Y.D. Yuan, Y.B. Yang, Y.Q. Yan, C.A. Akdis, Y.D. Gao, Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 75(7), 1730–1741 (2020).CrossRef
4.
W.-J. Guan, Z.-Y. Ni, Y. Hu, W.-H. Liang, C.-Q. Ou, J.-X. He, L. Liu, H. Shan, C.-L. Lei, D.S.C. Hui, B. Du, L.-J. Li, G. Zeng, K.-Y. Yuen, R.-C. Chen, C.-L. Tang, T. Wang, P.-Y. Chen, J. Xiang, S.-Y. Li, J.-L. Wang, Z.-J. Liang, Y.-X. Peng, L. Wei, Y. Liu, Y.-H. Hu, P. Peng, J.-M. Wang, J.-Y. Liu, Z. Chen, G. Li, Z.-J. Zheng, S.-Q. Qiu, J. Luo, C.-J. Ye, S.-Y. Zhu, N.-S. Zhong, Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 382, 1708–1720 (2020)CrossRef
5.
C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng, T. Yu, J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie, G. Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang, B. Cao, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020)CrossRef
6.
L. Fang, G. Karakiulakis, M. Roth, Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lancet. Respiratory Med. 8, e21 (2020)
7.
L. Zhu, Z.G. She, X. Cheng, J.J. Qin, X.J. Zhang, J. Cai, F. Lei, H. Wang, J. Xie, W. Wang, H. Li, P. Zhang, X. Song, X. Chen, M. Xiang, C. Zhang, L. Bai, D. Xiang, M.M. Chen, Y. Liu, Y. Yan, M. Liu, W. Mao, J. Zou, L. Liu, G. Chen, P. Luo, B. Xiao, C. Zhang, Z. Zhang, Z. Lu, J. Wang, H. Lu, X. Xia, D. Wang, X. Liao, G. Peng, P. Ye, J. Yang, Y. Yuan, X. Huang, J. Guo, B.H. Zhang, H. Li, Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 31, 1068–1077 e1063 (2020)CrossRef
8.
A. Extance, Covid-19 and long term conditions: what if you have cancer, diabetes, or chronic kidney disease? Bmj 368, m1174 (2020)CrossRef
9.
E.S. Moghissi, M.T. Korytkowski, M. DiNardo, D. Einhorn, R. Hellman, I.B. Hirsch, S.E. Inzucchi, F. Ismail-Beigi, M.S. Kirkman, G.E. Umpierrez, American Association of Clinical E, American Diabetes A: American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 32, 1119–1131 (2009)CrossRef
10.
S. Wang, P. Ma, S. Zhang, S. Song, Z. Wang, Y. Ma, J. Xu, F. Wu, L. Duan, Z. Yin, H. Luo, N. Xiong, M. Xu, T. Zeng, Y. Jin, Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. Diabetologia 63, 2102–2111 (2020)CrossRef
11.
C. Sardu, N. D’Onofrio, M.L. Balestrieri, M. Barbieri, M.R. Rizzo, V. Messina, P. Maggi, N. Coppola, G. Paolisso, R. Marfella, Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on Glycemic Control? Diabetes Care 43, 1408–1415 (2020)CrossRef
12.
S.P. Liu, Q. Zhang, W. Wang, M. Zhang, C. Liu, X. Xiao, Z. Liu, W.M. Hu, P. Jin, Hyperglycemia is a strong predictor of poor prognosis in COVID-19. Diabetes Res. Clin. Pract. 167, 108338 (2020)CrossRef
13.
J. Zhou, J. Tan, Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China. Metab.: Clin. Exp. 107, 154216 (2020)CrossRef
14.
S.R. Bornstein, F. Rubino, K. Khunti, G. Mingrone, D. Hopkins, A.L. Birkenfeld, B. Boehm, S. Amiel, R.I. Holt, J.S. Skyler, J.H. DeVries, E. Renard, R.H. Eckel, P. Zimmet, K.G. Alberti, J. Vidal, B. Geloneze, J.C. Chan, L. Ji, B. Ludwig, Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 8, 546–550 (2020)CrossRef
15.
A. Ceriello, A.P. Stoian, M. Rizzo, COVID-19 and diabetes management: What should be considered? Diabetes Res. Clin. Pract. 163, 108151 (2020)CrossRef
16.
X. Xia, K. Li, L. Wu, Z. Wang, M. Zhu, B. Huang, J. Li, Z. Wang, W. Wu, M. Wu, W. Li, L. Li, Y. Cai, B. Bosco, A. Zhong, X. Liu, T. Lv, Z. Gan, G. Chen, Y. Pan, C. Liu, K. Zhang, X. Xu, C. Wang, Q. Wang, Improved clinical symptoms and mortality on severe/critical COVID-19 patients utilizing Convalescent Plasma Transfusion. Blood 136(6), 755–759 (2020).CrossRef
17.
P.M. Grambsch, T.M. Therneau, Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81, 515–526 (1994)CrossRef
18.
N. Chen, M. Zhou, X. Dong, J. Qu, F. Gong, Y. Han, Y. Qiu, J. Wang, Y. Liu, Y. Wei, J. Xia, T. Yu, X. Zhang, L. Zhang, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395, 507–513 (2020)CrossRef
19.
D. Wang, B. Hu, C. Hu, F. Zhu, X. Liu, J. Zhang, B. Wang, H. Xiang, Z. Cheng, Y. Xiong, Y. Zhao, Y. Li, X. Wang, Z. Peng, Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 323(11), 1061–1069 (2020).CrossRef
20.
J.K. Yang, Y. Feng, M.Y. Yuan, S.Y. Yuan, H.J. Fu, B.Y. Wu, G.Z. Sun, G.R. Yang, X.L. Zhang, L. Wang, X. Xu, X.P. Xu, J.C. Chan, Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet. Med.: J. Br. Diabet. Assoc. 23, 623–628 (2006)CrossRef
21.
M. Raoufi, S. Khalili, M. Mansouri, A. Mahdavi, N. Khalili, Well-controlled vs poorly-controlled diabetes in patients with COVID-19: are there any differences in outcomes and imaging findings? Diabetes Res. Clin. Pract. 166, 108286 (2020)CrossRef
22.
Y. Li, X. Han, O. Alwalid, Y. Cui, Y. Cao, J. Liu, J. Gu, L. Wang, Y. Fan, H. Shi, Baseline characteristics and risk factors for short-term outcomes in 132 COVID-19 patients with diabetes in Wuhan China: a retrospective study. Diabetes Res. Clin. Pract. 166, 108299 (2020)CrossRef
23.
Q. Shi, X. Zhang, F. Jiang, X. Zhang, N. Hu, C. Bimu, J. Feng, S. Yan, Y. Guan, D. Xu, G. He, C. Chen, X. Xiong, L. Liu, H. Li, J. Tao, Z. Peng, W. Wang, Clinical characteristics and risk factors for mortality of COVID-19 patients with diabetes in Wuhan, China: A Two-Center, Retrospective Study. Diabetes Care 43, 1382–1391 (2020)CrossRef
24.
Y. Chen, D. Yang, B. Cheng, J. Chen, A. Peng, C. Yang, C. Liu, M. Xiong, A. Deng, Y. Zhang, L. Zheng, K. Huang, Clinical characteristics and outcomes of patients with diabetes and COVID-19 in Association With Glucose-Lowering Medication. Diabetes Care 43, 1399–1407 (2020)CrossRef
25.
M.E. Morra, L. Van Thanh, M.G. Kamel, A.A. Ghazy, A.M.A. Altibi, L.M. Dat, T.N.X. Thy, N.L. Vuong, M.R. Mostafa, S.I. Ahmed, S.S. Elabd, S. Fathima, T. Le Huy Vu, A.S. Omrani, Z.A. Memish, K. Hirayama, N.T. Huy, Clinical outcomes of current medical approaches for Middle East respiratory syndrome: a systematic review and meta-analysis. Rev. Med. Virol. 28, e1977 (2018)CrossRef
26.
M.A. Hill, C. Mantzoros, J.R. Sowers, Commentary: COVID-19 in patients with diabetes. Metab.: Clin. Exp. 107, 154217 (2020)CrossRef
27.
P. Zhang, L. Zhu, J. Cai, F. Lei, J.J. Qin, J. Xie, Y.M. Liu, Y.C. Zhao, X. Huang, L. Lin, M. Xia, M.M. Chen, X. Cheng, X. Zhang, D. Guo, Y. Peng, Y.X. Ji, J. Chen, Z.G. She, Y. Wang, Q. Xu, R. Tan, H. Wang, J. Lin, P. Luo, S. Fu, H. Cai, P. Ye, B. Xiao, W. Mao, L. Liu, Y. Yan, M. Liu, M. Chen, X.J. Zhang, X. Wang, R.M. Touyz, J. Xia, B.H. Zhang, X. Huang, Y. Yuan, L. Rohit, P.P. Liu, H. Li, Association of inpatient use of Angiotensin-Converting Enzyme inhibitors and Angiotensin II Receptor Blockers With mortality among patients with hypertension Hospitalized with COVID-19. Circulation Res. 126, 1671–1681 (2020)CrossRef
28.
R. Pal, A. Bhansali, COVID-19, diabetes mellitus and ACE2: The conundrum. Diabetes Res. Clin. Pract. 162, 108132 (2020)CrossRef
29.
M. Hoffmann, H. Kleine-Weber, S. Schroeder, N. Kruger, T. Herrler, S. Erichsen, T.S. Schiergens, G. Herrler, N.H. Wu, A. Nitsche, M.A. Muller, C. Drosten, S. Pohlmann, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280 e278 (2020)CrossRef
30.
F. Rubino, S.A. Amiel, P. Zimmet, G. Alberti, S. Bornstein, R.H. Eckel, G. Mingrone, B. Boehm, M.E. Cooper, Z. Chai, S. Del Prato, L. Ji, D. Hopkins, W.H. Herman, K. Khunti, J.C. Mbanya, E. Renard, New-onset diabetes in Covid-19. N. Engl. J. Med. 383(8), 789–790 (2020).CrossRef
31.
T. Sathish, R.J. Tapp, M.E. Cooper, P. Zimmet, Potential metabolic and inflammatory pathways between COVID-19 and new-onset diabetes. Diabetes Metab. 47, 101204 (2021)CrossRef
32.
T. Sathish, N. Kapoor, Y. Cao, R.J. Tapp, P. Zimmet, Proportion of newly diagnosed diabetes in COVID-19 patients: a systematic review and meta-analysis. Diabetes Obes. Metab. 23, 870–874 (2021)CrossRef
33.
Q. Wang, P. Fang, R. He, M. Li, H. Yu, L. Zhou, Y. Yi, F. Wang, Y. Rong, Y. Zhang, A. Chen, N. Peng, Y. Lin, M. Lu, Y. Zhu, G. Peng, L. Rao, S. Liu, O-GlcNAc transferase promotes influenza A virus-induced cytokine storm by targeting interferon regulatory factor-5. Sci. Adv. 6, eaaz7086 (2020)CrossRef
34.
M. Catanzaro, F. Fagiani, M. Racchi, E. Corsini, S. Govoni, C. Lanni, Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct. Target. Ther. 5, 84 (2020)CrossRef
35.
M.F. Konig, M. Powell, V. Staedtke, R.Y. Bai, D.L. Thomas, N. Fischer, S. Huq, A.M. Khalafallah, A.Koenecke, R.Xiong, B.Mensh, N.Papadopoulos, K.W.Kinzler, B.Vogelstein, J.T.Vogelstein, S.Athey, S.Zhou, C.Bettegowda, Preventing cytokine storm syndrome in COVID-19 using alpha-1 adrenergic receptor antagonists. J. Clin. Invest. 130(7), 3345–3347 (2020).CrossRef
36.
A.J. Scheen, M. Marre, C. Thivolet, Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports. Diabetes Metab. 46, 265–271 (2020)CrossRef
37.
K. Khunti, P. Knighton, F. Zaccardi, C. Bakhai, E. Barron, N. Holman, P. Kar, C. Meace, N. Sattar, S. Sharp, N.J. Wareham, A. Weaver, E. Woch, B. Young, J. Valabhji, Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. Lancet Diabetes Endocrinol. 9, 293–303 (2021)CrossRef
38.
O. Kamyshnyi, V. Matskevych, T. Lenchuk, O. Strilbytska, K. Storey, O. Lushchak, Metformin to decrease COVID-19 severity and mortality: Molecular mechanisms and therapeutic potential. Biomedicine Pharmacother. 144, 112230 (2021)CrossRef
Metadata
Title
Association of blood glucose level and prognosis of inpatients with coexistent diabetes and COVID-19
Authors
Weiwei Duan
Liangyu Li
Xuesong Li
Mengyan Zhu
Lingxiang Wu
Wei Wu
Kening Li
Yuan Liang
Rong Ding
Wenhua You
Ziyu Wang
Bin Huang
Min Wu
Tingting Zhang
Jie Li
Yan Li
Jiaofang Shao
Changsong Lin
Pengping Li
Qianghu Wang
Shukui Wang
Xinyi Xia
Yu Liu
Sali Lyu
Publication date
01-01-2022
Publisher
Springer US
Published in
Endocrine / Issue 1/2022
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-021-02923-7

Other articles of this Issue 1/2022

Endocrine 1/2022 Go to the issue

Review

A contemporary clinical approach to genetic testing for heritable hyperparathyroidism syndromes

Letter to the Editor

Comment on Li et al. Serum lipids are novel predictors for thyroid autoimmunity in the general population with normal TSH levels from a cross-sectional study

Original article

Effect of very low-calorie ketogenic diet in combination with omega-3 on inflammation, satiety hormones, body composition, and metabolic markers. A pilot study in class I obese subjects

Original Article

Low sclerostin levels after long-term remission of acromegaly

Original Article

Chronic angiotensin receptor activation promotes hepatic triacylglycerol accumulation during an acute glucose challenge in obese-insulin-resistant OLETF rats

Original Article

Association of body mass index with serum anti-Müllerian hormone and inhibin B levels among 8323 women attending a reproductive medical center: a cross-sectional study

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits